covid and tirzepatide Can a GIP/GLP-1 dual receptor agonist help treat long COVID? A new nationwide clinical trial led by scientists at the Scripps Research Translational Institute is putting that question to the test. The Our Studies - Long COVID

The battle between GLP-1 receptor agonists (semaglutide) and dual GLP-1/GIP agonists (tirzepatide) is reshaping both diabetes & obesity treatment

A University of Mississippi-led study found that insurers would have to offer more services than just the medication to produce long-term cost savings

DOI: 10.1073/pnas.2536772123 JOURNAL Proceedings of the National Academy of Sciences AUTHORS Sam Van de Velde, Jungting Yu, K

If you are seeking guidance as to whether our Newport Beach Medical Weight Loss Programs are right for you, schedule a consultation today by calling 949.867.0091 Benefits of the Semaglutide and Tirzepatide Weight Loss Program Choosing our weight loss program with Semaglutide (GLP-1) Ozempic and Tirzepatide (GLP-1/GIP) Mounjaro offers several advantages: Clinically Proven Results: Semaglutide and Tirzepatide have been shown to significantly reduce body weight in clinical studies

Esclim (estradiol transdermal)

The decision tree matters